Authors

Evaluating Clinical Safety of BTK Inhibitors: Cardiovascular Events and Drug-Drug Interactions

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Community Pharmacy Credentialing: Why Part D Coverage No Longer Guarantees Part B Payment

As pharmacies expand into offering immunizations and other clinical services, the rules for the Part B medical side have moved away from the traditional pharmacy side.

Improve Skin Health Through Student Pharmacist Education

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says

John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.

Some Pharmacists Find Better Balance in New Zealand

Some pharmacists are exploring the possibilities of moving to New Zealand for better work/life balance.

Advancing Precision Oncology Through Pharmacy-Led Innovation

Precision oncology has shifted, yet pharmacists’ roles remain underutilized.

Medetomidine in the Illicit Drug Supply: What Pharmacists Need to Know About "Rhino Tranq" and Naloxone-Resistant Overdoses

As medetomidine rapidly displaces xylazine as a fentanyl adulterant, pharmacists must recognize its distinct toxidrome, understand why naloxone alone is insufficient, and support updated harm reduction strategies in an increasingly complex overdose landscape.

Beyond the Dispensing Counter: Community Service and Volunteerism Spur Growth

Volunteer service strengthens pharmacists’ empathy, confidence, and communication, boosting patient trust, teamwork, and community connection.

The Role of Executive Orders

These directives are typically used to shape federal agencies and manage employees in the executive branch.

Understand the Use of Panzyga for Immune-Related Disorders

Pharmacists should educate patients about their treatment regimen and potential adverse effects.

Dordaviprone: Safety, Efficacy, and Implications for Pharmacy Practice

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

Olympic Athlete Tabitha Peterson, PharmD, on Supporting Safe Performance in Sports

Olympic athlete Tabitha Peterson, PharmD, reveals how sports pharmacy helps athletes avoid antidoping risks, manage supplements safely, and stay competition-ready.

Implementing CDC’s Core Elements of Sepsis

The agency outlines key elements for building effective hospital sepsis programs.

ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk

New SYNCHRONIZE data signal broad metabolic and hepatic benefits.

Biosimilar Adoption: The Pharmacist's Role in Formulary Decisions, Patient Counseling, and Safe Use

Biosimilars lower biologic costs and widen access.

Pharmacy Logistics, Emerging Safety and Efficacy Data, and Future Directions for Menin Inhibitors in Acute Leukemias

Targeted menin inhibitors offer new hope for patients with difficult-to-treat acute leukemias.

The Expanding Role of CDK 4/6 Inhibitors in Breast Cancer Treatment

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.

ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says

John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.

Rethinking Escalation in Relapsing MS

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Patricia K. Coyle, MD, a Director at the MS Center at Stony Brook Medicine, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking escalation strategies in relapsing MS.

Pharmacists Can Intervene in Commonly Overlooked Medication Errors

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

GLP-1s: A New Frontier in Substance Use Disorder Management

New trials explore glucagon-like peptide-1 receptor agonists for alcohol, nicotine use disorder, and smoking cessation.

Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Flushing the Old Away: Transitioning From Heparin to Saline for Implanted Port Maintenance

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Exploring the Antidepressant Potential of GLP-1 Receptor Agonists

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

More Options, More Questions: How Pharmacists Are Managing EGFR-Positive Non-Small Cell Lung Cancer

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

Medication Management and Supply Chain Still Underwater: Challenges and Future Trends in Health Care

From Inpatient to Outpatient: A Pharmacy-Led Evolution in Transplant Care

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

How Medication Stigma and Bias Can Impact Patient Recovery

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how medication stigma and bias can impact patient recovery.

Paradoxical Hypotension After Inadvertent Intravenous Administration of Epinephrine

Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.